Answers are grounded in this paper and cite their sources.
We uncovered a mechanism of ITGB2-mediated EGFR activation in SCLC that explains EGFR-inhibitor resistance independently of EGFR mutations, suggesting the development of therapies targeting ITGB2 for patients with this extremely aggressive lung cancer type.
No takes yet. Share an insight, caveat, or question.
Rubio et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: